2-Fluorodeschloroketamine Rapid Antidepressant Effect

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for depression, particularly for treatment-refractory or treatment-resistant depression, have a slow onset of action, taking weeks to months to achieve full effects, leading to significant morbidity and risk of suicidal behavior.

Innovation Solution

The administration of 2-fluorodeschloroketamine (2-FDCK), which has a flatter dose-response curve compared to S-ketamine, potentially reducing side effects and allowing for patient self-administration, thereby offering a rapid antidepressant effect.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional antidepressants are used to treat depression, then the treatment can be safely administered, but the onset of action is slow (weeks to months), leading to prolonged suffering and increased risk of suicidal behavior

Engineering Contradiction:

Improvesafety of administrationVSAvoidonset of action time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of ketamine through fluorodechloroketamine substitution, which alters the pharmacokinetic and pharmacodynamic parameters to achieve rapid antidepressant effects within hours while maintaining safety through a flatter dose-response curve

Inventive Principle:

Principle #35Parameter changes

2Speed

If ketamine is used to achieve rapid antidepressant effect, then the onset of action is fast (within hours), but the dose-response curve is steep, increasing the risk of side effects and limiting patient self-administration

Engineering Contradiction:

Improveonset of antidepressant effectVSAvoidside effects

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical parameters of ketamine by replacing the chlorine atom with fluorine at the 2-position, which changes the dose-response characteristics to produce a flatter curve, thereby maintaining rapid efficacy while reducing the incidence and severity of adverse effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite pharmacological profile by combining the rapid-acting properties of ketamine with the improved safety margin of fluorinated analogs, achieving a balanced therapeutic agent that offers both speed and safety

Inventive Principle:

Principle #40Composite materials

3Productivity

If S-ketamine is administered to treat treatment-resistant depression, then rapid antidepressant effects are achieved, but the steep dose-response curve requires strict medical supervision and prevents patient self-administration

Engineering Contradiction:

Improvetreatment efficiencyVSAvoidpatient self-administration capability

Core Design Contradiction:

ProductivityVSEase of operation

Solution Approach 1:

The patent changes the dosing parameters through fluorodechloroketamine modification, which broadens the therapeutic window and flattens the dose-response curve, enabling patients to self-administer at home without requiring strict medical supervision while maintaining treatment efficiency

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250032429A12-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression

Publication Date: 2025.01.30 CLEARMIND LABS CORP

AI summary

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that administering 2-fluorodeschloroketamine (2-FDCK) is effective to treat depression, especially to treat treatment-resistant depression.